Institut National De La Sante Et De La Recherche Medicale

Assistance Publique-Hopitaux De Paris

Université Paris Diderot-Paris 7

Universite Paris Xiii Paris-Nord

Institut Pasteur

Universite Paris Cité

Inserm

Erick Denamur

Olivier Clermont

Laurent Debarbieux

Jean-Damien Ricard

Tony Le Gall

Nicolas Dufour

Olivier Tenaillon

The present invention relates to a bacteriophage strain capable of producing a lytic infection in theST131-025b:H4 clone. The burden of ST131-025b:H4clonal complex in human community and hospital-acquired infections is increasing worldwide, going along with a worrying and growing resistance to betalactams and fluoroquinolones. Bacteriophage LM33_P1 infects exclusively (100% specificity) 025bstrains with 70% coverage on the two major antibiotic resistant pandemic clonal complexes ST131-025b:H4 and ST69-025b. The inventors evaluated the in vivo activity of bacteriophage LM33_P1 using three different extraintestinal virulence murine models and showed that it infects bacteria in several organs. In particular, the invention relates to a bacteriophage capable of producing a lytic infection in theST131-025b:H4 clone comprising a polypeptide corresponding to the bacteriophage tail fiber protein and responsible for the attachment of the bacteriophage to theST131-025b:H4 clone.

Bacteriophage strain capable of producing a lytic infection in theST131-025B:H4 clone

The present invention relates to human specificstrains.

[object Object]

Growing community of inventors

Paris, France

Erick Denamur